Abstract
Tissue-agnostic drug development is a major step forward in offering treatment options for rare tumors. Sarcomas are heterogeneous rare malignancies with more than 100 subtypes. Recent failure of Phase III trials, nonbiomarker-driven clinical trials, and rarity hamper developmental therapeutics in sarcomas. Since a ‘one-size-fits-all’ approach continues to be the standard of care, tissue-agnostic approvals assume significance in sarcomas. In this review, we focus on the clinical evidence of recent drug approvals for neurotrophic tyrosine receptor kinase (NTRK) fusion, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) phenotype, and tumor mutation burden-high (TMB-H) status in the context of sarcomas, and the future landscape of tissue-agnostic targets, such as rearranged during transfection (RET), fibroblast growth factor receptor (FGFR), and neuregulin-1 (NRG1).
Original language | English (US) |
---|---|
Pages (from-to) | 135-144 |
Number of pages | 10 |
Journal | Trends in Cancer |
Volume | 8 |
Issue number | 2 |
DOIs | |
State | Published - Feb 2022 |
Keywords
- MSI-H
- NTRK
- RET
- TMB-H
- biomarker
- genomics
- histology-agnostic
- sarcoma
- tissue-agnostic
ASJC Scopus subject areas
- Oncology
- Cancer Research